• Ai Wang, Muisha Bienvenue Mbikyo, Junzhe Zhang, Nan Cui, and Zhao Li.
• Department of Cardiology, The First Hospital of China Medical University, Shenyang, China.
• J Coll Physicians Surg Pak. 2024 Apr 1; 34 (4): 383389383-389.

ObjectiveTo evaluate the efficacy and safety of pharmacogenomics (PGx)-guided treatment in individuals with resistant hypertension (RH).Study DesignRandomised controlled open-label study. Place and Duration of the Study: Department of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning Province, China, from June 2019 to November 2021.MethodologyThe study assigned RH patients to two groups. The intervention group (IG) received 12 weeks of PGx-guided treatment, while the control group (CG) followed a consensus-based approach. Examining 10 genes and their alleles with 31 antihypertensive drugs in the IG, the study provided specific medication advice. The primary outcome measured the difference in office systolic blood pressure (SBP) change from baseline at 12 weeks. Secondary outcomes included changes in diastolic blood pressure (DBP), hepatic and renal function, and major adverse cardiovascular events.ResultsFifty-nine patients from the First Hospital of China Medical University participated, with 29 in the IG and 30 in the CG. Significant differences were noted in SBP reduction (IG: 31.26 ± 18.64 mmHg; CG: 14.61 ± 17.74 mmHg; p=0.001) and DBP reduction (IG: 19.61 ± 17.32 mmHg; CG: 7.81 ± 11.23 mmHg; p = 0.003) after 12 weeks. One IG patient had a heart attack, and one CG subject developed heart failure. At week 12, hepatic insufficiency was observed in one IG patient and six CG patients, while renal insufficiency occurred in five patients of both groups.ConclusionTreatment guided by PGx demonstrated significant reductions in both SBP and DBP compared to consensus-based treatment.Key WordsResistant hypertension, Treatment, Pharmacogenomics, Clinical study.

9 keywords...

hide…